Brief: Arcus Bioscience Announces First Overall Survival Results From Phase 2 Edge-Gastric Study
12/10/2025 23:10
Oct 12 (Reuters) - Arcus Biosciences Inc RCUS.N: ANTI-TIGIT DOMVANALIMAB PLUS ANTI-PD-1 ZIMBERELIMAB AND CHEMOTHERAPY SHOWED 26.7 MONTHS OF MEDIAN OVERALL SURVIVAL AS FIRST-LINE TREATMENT OF UNRESECTABLE OR ADVANCED GASTROESOPHAGEAL ADENOCARCINOMAS IN THE PHASE 2 EDGE-GASTRIC STUDY ARCUS BIOSCIENCES INC - NO UNEXPECTED SAFETY SIGNALS OBSERVED IN STUDY Source text: ID:nBw6WFSXfa Further company coverage: RCUS.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcus Biosciences
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Arcus Biosciences tumbles on $250 mln share sale
Brief: Arcus Biosciences Announces Pricing Of $250 Million Public Offering Of Common Stock
Arcus Biosciences drops after starting stock offering